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In recent years an increasing number of pregnant women at risk of pregnancy-induced hypertensive disorders and fetal growth retardation are being prescribed low-dose aspirin,' although its prophylactic effect remains disputed.'-" Aspirin in analgesic doses may have an antifibrinolytic effect, because it inhibits the endothelial release of tissue-type plasminogen activator (tPA) after venous occlusion.'~ ' This effect could be mediated by inhibition of prostacyclin (PGI,) synthesis because it is reversed by a synthetic PGI, ana1og.7 Low-dose aspirin, 20 mg for 7 days, did not afect fibrinolytic activity after venous occlusion in healthy males.8 Although low-dose aspirin primarily inhibits platelet thromboxane synthesis, it may also cause a small reduction in PGI, synthesis in nonpregnant individual? and in pregnant women."
For that reason an effect of long-term low-dose aspirin on the fibrinolytic system of the pregnant woman cannot be excluded. Modulation of the fibrinolytic system by low-dose aspirin could be of particular importance after normal placental separation, when coagulation in the placental bed is balanced by a marked increase in fibrinolytic capacity."
In this study we compared variables of fibrinolysis and thromboxane and PGI, synthesis at the end of pregnancy before and immediately after parturition in women receiving low-dose aspirin for prevention of preeclampsia or fetal growth retardation and in women who had not taken aspirin. Because exact definition of the timing of sampling could be important in an investigation on fibrinolytic variables, we conducted this study in plasma of women in whom labor was induced, which allowed standardization of sampling times. In addition, we investigated the effect of low-dose aspirin on fibrinolytic variables in cord blood.
Material and methods
Patients. Twenty-four healthy pregnant women were enrolled in the study. Of these, eight took a daily dose of 60 to 80 mg of aspirin (1 mgikg body weight) from 12 weeks' gestation until delivery because of a history of preeclampsia or fetal growth retardation; 16 women who did not use aspirin during pregnancy served as controls. All women opted for elective induction of for determination of tPA antigen, plasminogen activator inhibitor type-l (PAI-1) and type-2 (PAI-2) antigen and plasminogen activator inhibitor activity. Another 4.5 ml sample was collected in Stabilyte tubes (Biopool, Umea, Sweden, containing 0.5 ml of 0.45 mol/L sodium citrate buffer, pH 4.3) for determination of tPA activity. A 9 ml sample was taken in a plastic tube in 1 ml of disodium ethylenediaminetetraacetate for determination of synthesis of malondialdehyde by stimulated platelets. For determination of 6-keto-prostaglandin F,, (PGF,,), a stable metabolite of PGI,, a 5 ml sample was collected in cooled plastic tubes containing 10 ~1 of heparin and 25 ~1 of indomethacin (0.1% in potassium-phosphate buffer 0.1 mol/L, pH 7.4). Finally, a 5 ml blood sample was collected in glass tubes and allowed to clot for determination of serum levels of thromboxane B, (TXB,). Samples of mixed free-flowing cord blood were collected immediately after clamping of the cord with the placenta in situ for determination of the same set of variables.
Analytic procedures. Samples for determination of variables of fibrinolysis were transported on melting ice, centrifuged for 30 minutes at 20009 at 4" C, and stored at -70" C until analysis. Samples for determination of plasma PGF,, were centrifuged for 10 minutes at 15OOg at 0" C and stored at -20" C until analysis. The clotted blood samples for determination of serum TXB, were incubated for 60 minutes at 37" C to stimulate maximum platelet TXB, release. After centrifugation for 10 minutes at 25009 at 20" C serum samples were kept at -20" C until analysis. tPA antigen was determined with a commercially available enzyme immunoassay (Imulyse, Biopool) that measures both free and complexed tPA in the range of 1.5 to 30 ngiml. The maximal sensitivity of the test was 1.5 rig/ml; intraassay variation was 8% and interassay variation 10%. tPA activity was determined by the conversion of plasminogen to plasmin in the presence of soluble fibrinogen fragments by means of a chromogenic substrate according to Verheijen et a1.l4 The detection limit of this assay was 50 mIU/ml; intraassay variation was 5% to 13%, and interassay variation was 15% to 20%.
PAIantigen was measured with a commercially available enzyme immunoassay that used anti-PAI-1 antibodies (TintElize PAI-1, Biopool). The test measures both fi-ee PAI-and PAI-complexed to activators. The detection limit was 2 rig/ml PAI-1; the intraassay variation was 2% at 40 rig/ml and 7% at 15 rig/ml. Intraassay variation was 2% to lo%, and interassay variation was 10% to 15%.
PAIantigen was determined with a commercially available enzyme immunoassay that used anti-PAT-2 antibodies (TintElize PAI-2, Biopool). The detection limit was 6 ngiml.
The capacity of platelets to synthesize thromboxane AZ was determined within 30 minutes after venipuncture by measuring the amount of its stable by-product malondialdehyde produced on stirring platelet-rich plasma with thrombin
(1 IU/ml final concentration), as described previously.'@ The concentration of malondialdehyde was measured by means of the thiobarbituric acid reaction and expressed as nanomoles of malondialdehyde produced by 10' platelets. Plasma concentrations of PGF,, and serum TXB, levels were determined by radioimmunoassay (E.I. Du Pont de Nemours-NEN Research Products, Boston). A Sep-Pak Cl8 cartridge (Waters, Milford, Mass.) was prewashed with 10 ml of absolute ethanol, 10 ml of distilled water, and 2 ml of air. Two milliliters of the sample was applied to the column, followed by 2 ml of distilled water and 2 ml of air. The prostaglandin metabolites were eluated with 2 ml of absolute ethanol, followed by 2 ml of air, and the eluate was brought to dryness at 40" C under a gentle stream of nitrogen. 
Results

General characteristics
of the women who participated in the study are summarized in Table I . None of the aspirin-treated women had a pregnancy-induced hypertensive disorder or fetal growth retardation. All deliveries were uncomplicated and resulted in live, healthy infants.
Effects of labor and delivery on fibrinolytic markers are presented in Table II . Concentrations of tPA antigen, tPA activity, PAIantigen, and PAIantigen before labor and after delivery of the placenta were not different between aspirin users and controls. Plasminogen activator inhibitor activity was significantly reduced in the aspirin group compared with controls, before and after parturition (p = 0.02). Both tPA antigen and activity rose, whereas PAIantigen and plasminogen activator inhibitor activity decreased significantly during labor and delivery. These changes were not affected by low-dose aspirin and were not related to the duration of labor. PAIantigen showed a small but significant @ = 0.03) reduction during parturition in the control group that could not be demonstrated in low-dose aspirin users. No significant correlations were demonstrated between the levels of fibrinolytic variables in maternal and cord plasma. Comparison of fibrinolytic variables in cord blood in the aspirin and control groups showed no significant differences (Table III) .
Levels of PGF,, before labor in the aspirin group (median 54.7 rig/L, range 52 to 82.8 rig/L) were about 14% lower than in controls (median 63.3 rig/L, range 50.6 to 73 rig/L), but the difference was not significant. Fig. 1 , A and B, shows the significant increase in PGF,, in maternal plasma during parturition; no significant differences could be demonstrated between the aspirin and control groups. Cord plasma levels of PGF,, were not different between groups and were about 14 times higher than maternal plasma concentrations (p < 0.001 in aspirin users and in controls. In the control group no differences could be demonstrated between platelet malondialdehyde synthesis and serum TXB, concentrations in maternal and cord samples, but in low-dose aspirin users malondialdehyde synthesis and serum TXB, concentrations were significantly reduced in maternal compared with cord samples @ < 0.001).
Comment
Results of previous studies suggest that a daily dose of 60 to 80 mg of aspirin has no demonstrable effect on hemostasis in pregnant women, as indicated by the bleeding time, '*, I9 but no data could be found in the accessible literature on the effect on the fibrinolytic system. Throughout pregnancy marked alterations occur in the fibrinolytic system, characterized by increases in plasma concentrations of tPA and its inhibitors PAIand PAIuntil the end of the thirty-eighth week of pregnancy, after which plasma concentrations of all these substances decrease, except those of tPA antigen."' In a recent report on the effects of parturition on fibrinolysis a significant increase in maternal plasma concentrations of tPA antigen during labor was demonstrated, with a marked further increase in fibrinolytic potential after placental separation.*'
In previous studies a high dose of aspirin (650 mg) ingested 18 and 2 hours before blood sampling was shown to inhibit the release of tPA antigen by vascular endothelium induced by venous occ1usion.5' ' A study of the effect of 20 mg of aspirin taken for 7 consecutive days showed no significant effect on fibrinolytic activity, measured by the euglobulin lysis area and the euglobulin lysis time.' In our study no effect of the long-term use of low-dose aspirin on tPA activity was observed. The only fibrino- Bremer et al. March 1995 Am J Obstet Gynecol lytic variable affected by the use of low-dose aspirin during pregnancy was plasminogen activator inhibitor activity, which was significantly reduced in the aspirin group before and after labor. This could lead to a relative dominance of tPA activity over plasminogen activator inhibitor and hence to an increased fibrinolytic potential in low-dose aspirin users. The question whether this causes an increase in effective fibrinolysis in vivo remains to be answered. The observed significant changes in levels of all fibrinolytic markers during parturition, except PAI-2, may be caused by vascular damage in the uterine placental bed" and appear to remain unaffected by low-dose aspirin. In the nonpregnant state diurnal variations in blood fibrinolytic activity are caused by changes in the plasma levels of PAI-I, which are highest in the early morning and lowest in the late afternoon.'3 However, plasminogen activator inhibitor production is not influenced by diurnal variations in populations with high plasminogen activator inhibitor levels, as in pregnancy.24 Because of the standardization of our study, all samples were obtained at approximately the same time of the day, which makes a contribution of circadian variation to the results unlikely.
We could not demonstrate an inhibitory effect of the long-term intake of 60 to 80 mg of aspirin on maternal PGI, synthesis, which confirms earlier observations by ourselves"
and by others." The observed increased synthesis of PGI, during labor confirms earlier observation?" and appears also to be unaffected by low-dose aspirin.
It is known that in normal pregnancy platelet reactivity increases, not only in association with increasing activity of the cyclooxygenase pathway but also with an elevated sensitivity of the platelet membrane."7 Previous studies have shown that approximately 90% to 95% inhibition of maternal platelet reactivity can be achieved with a daily dose of 60 mg of aspirin,", " as confirmed in the current study. Negatively charged phospholipids are known to stimulate plasminogen activator inhibitor activity,"' and platelets, offering a net negative charge on activation, may provide a site for activation of plasminogen activator inhibitor.30 Therefore the reduced platelet reactivity induced by low-dose aspirin could be responsible for the reduced plasminogen activator inhibitor activity in the aspirin group. 
